We sought to investigate the impact of six months of cardiac resynchronization therapy (CRT) on echocardiographic variables of left ventricular (LV) function. BACKGROUND Cardiac resynchronization therapy has recently been introduced as a new therapeutic modality in patients with advanced heart failure (HF) and conduction abnormalities. However, most studies have only investigated the early hemodynamic effects of CRT.
The design and inclusion and exclusion criteria of the study have been described previously (6) . In brief, patients with HF of both ischemic and nonischemic origin were included if they were in New York Heart Association (NYHA) functional class III or IV HF and had sinus rhythm, a PR interval Ն150 ms and a QRS width Ͼ120 ms in at least two surface electrocardiographic (ECG) leads. QRS durations were automatically measured as the maximum of leads II, V 1 and V 6 and validated manually by two independent observers. All patients underwent implantation of two separate DDD pacemakers-one connected to a right atrial and right ventricular (RV) screw-in pacing lead (Sweet-Tip, Guidant Corp.) and the other connected to another right atrial and epicardial LV pacing lead (model 4316, Guidant Corp., or model 4965, Medtronic)-by a limited thoracotomy. This configuration allowed for a change of the pacing site from RV to LV and BV pacing both during implantation and at long-term follow-up. Biventricular pacing was achieved by programming one device in the VDD mode and the second device in the ventricular triggered mode (VVT). Early hemodynamic testing. All patients underwent early hemodynamic testing during pacemaker implantation, under general anesthesia. Two 8F dual-transducer pressure catheters (model SPC-780c, Millar Instruments) were placed to measure the right atrial, RV, LV and aortic pressures. Pressure catheters and pacing leads were connected to a customized external pacing computer (FlexStim, Guidant Corp.) to acquire hemodynamic signals and execute an early pacing protocol (FlexStim protocol) (6) . The FlexStim protocol is designed to measure the immediate effects of pacing, account for local baseline shifts and allow statistical comparison of multiple pacing combinations within individuals. Briefly, the RV, LV or both ventricles were stimulated in the VDD mode at one of five atrioventricular delays preset to a percentage of the patient's intrinsic PR interval, as measured with the pacing leads. Each combination of pacing chamber and atrioventricular delay was randomly repeated five times by pacing for five beats separated by 15 nonpaced beats. The hemodynamic variables used to determine the optimized pacing mode were the changes in aortic pulse pressure and maximal upward slope of the LV systolic pressure curve (ϩdP/dt) (2). Pacing protocol. For intra-individual comparisons of the primary end point of the trial-improvement of functional capacity (6)-patients were randomized to one month of optimized univentricular or BV pacing followed by one month of no pacing. During the third month, patients were crossed over to the other pacing mode. After three months, all patients were paced in the mode with the optimal early response during intra-operative testing. The functional status of the patient was assessed by a physician who had no knowledge of the pacing mode before implantation and after six months. Twenty-five patients (13 men and 12 women; 60 Ϯ 5 years old) were analyzed; 17 patients had to be excluded for the following reasons: 4 patients died (1 due to sudden cardiac death, 1 due to nonsudden cardiac death, 1 due to liver cancer, 1 postoperatively [this patient was later classified as having an inclusion criteria violation, according to the Data Safety Monitoring Committee, because of an underestimated aortic stenosis]); 1 patient was in atrial fibrillation at the six-month follow-up; 1 patient underwent cardiac transplantation; 3 patients were not effectively paced because of an increased LV pacing threshold; and 1 patient withdrew consent. In the remaining seven patients, either one of the echocardiograms was judged as insufficient for reliable analysis by one or both independent observers. Echocardiographic measurements. Transthoracic echocardiography was performed shortly before pacemaker implantation during intrinsic conduction and after six months when patients were paced with the optimal mode and settings. Left atrial and LV diameters were determined using M-mode echocardiography under two-dimensional guidance in the parasternal long-axis view, according to the guidelines of the American Society of Echocardiography (7) . Left ventricular mass was calculated according to the Penn convention (8) . The end of diastole was defined by the onset of the QRS complex in the simultaneously recorded ECG; the end of systole was defined by the smallest cavity area before mitral valve closure. For measurement of LV end-systolic and end-diastolic dimensions (LVEDD and LVESD, respectively), images were obtained in the apical two-and four-chamber views. Percent fractional shortening was calculated as: (LVEDDϪLVESD)/LVESD ϫ 100. Longitudinal and transverse LV diameters were measured in the apical four-chamber view at end diastole, and the sphericity index was calculated as the LV transverse diameter/longitudinal diameter ratio (9) . Biplane LV endsystolic and end-diastolic volumes (LVESV and LVEDV, respectively) were calculated from the two-chamber and four-chamber views, according to the modified Simpson's rule (10); measurements were averaged from three cardiac cycles. Left ventricular EF was calculated as: ͑LVEDV Ϫ LVESV͒/LVEDV ϫ 100. Patients were classified as volume "responders" if LVESV decreased by Ͼ15%, as "stable" if LVESV changes were Յ15% and as "nonresponders" if LVESV increased by Ͼ15%, based on data AV ϭ atrioventricular; BBB ϭ bundle branch block; BV ϭ biventricular; ϩdp/dt ϭ maximal rise of left ventricular pressure; EDV and ESV ϭ end-diastolic and end-systolic volume, respectively; EF ϭ ejection fraction; IVCD ϭ intraventricular conduction disturbance; LBBB and RBBB ϭ left and right bundle branch block, respectively; LV ϭ left ventricle; NYHA ϭ New York Heart Association; PP ϭ pulse pressure; RV ϭ right ventricle. showing a variability of Յ15% for repeated volume calculations derived from two-dimensional echocardiographic measurements (11) . For statistical analysis, responders and stable patients were analyzed as one group, because both reduced and stable volumes were regarded as a positive clinical response to CRT. Mitral regurgitation (MR) was semiquantitatively graded on a 4-point scale (grades 0 to 3) using color-coded Doppler signals, as previously described (12) , and the maximal jet area was measured in the parasternal and apical views (13) . All examinations were recorded, stored on videotape and analyzed at the responsible core center (RWTH University of Technology, Aachen, Germany). Final analysis was performed off-line (from videotape) by two independent observers, after manual recalibration on an Agilent Sonos 2500 ultrasound scanner.
Concomitant drug treatment.
Patients had to be in stable NYHA functional class III HF without a change in medication or in class IV without the need for intravenous inotropic drugs during the last month to be eligible for study inclusion. Of the 25 patients, 24 (96%) were taking angiotensin-converting enzyme inhibitors, 22 (88%) were receiving digitalis, and 11 (44%) were receiving nitrates. Of 14 patients (56%) initially taking beta-blockers, the dosage was constant in nine, reduced in two and increased in three after six months. In only one patient was a beta-blocker started during the study period. Of 24 patients (96%) taking diuretics before implantation, the dosage was kept constant in 12, reduced in 10 and increased in two. One patient began to receive diuretics during the six-month period, whereas diuretics were withdrawn in one patient. Statistical analysis. The statistical methods used for analysis of the invasively measured hemodynamic variables have been described elsewhere (2) . In brief, relative changes of ϩdP/dt and pulse pressure (%) in the second to fifth paced beats of each run of five paced beats were compared with the average value during the immediately preceding six nonpaced beats. A paired t test was used to evaluate the effects of pacing compared with no pacing. Cardiac dimensions and volumes were compared intra-individually by using a paired t test. Baseline volumes were compared with early changes in ϩdP/dt and pulse pressure by using linear regression analysis. All numeric data are expressed as the mean value Ϯ SD. A p value Ͻ0.05 was considered significant. Interobserver and intra-observer variabilities were defined as the difference of measurements between two observers, expressed as the percent difference (Ϯ SD) of the first observer.
RESULTS
Baseline evaluation. Table 1 shows the clinical data of the 25 analyzed patients. The ECG pattern of intraventricular conduction delay was classified as left bundle branch block (LBBB) type in 21 patients (84%), right bundle branch block type in one patient (4%) and intraventricular conduction delay in three patients (12%), according to previously published criteria (14) . The optimal pacing site was BV in 12 (48%), LV in 10 (40%) and RV in 3 patients (12%). The mean NYHA functional class improved from 3.0 Ϯ 0.1 at baseline to 1.9 Ϯ 0.7 after six months of CRT, with no difference between volume responders and stable patients (n ϭ 21; from 3.0 Ϯ 0.2 to 1.9 Ϯ 0.7) and volume nonresponders (n ϭ 4; from 3.0 Ϯ 0 to 2.1 Ϯ 0.9; p ϭ NS). Changes in LV dimensions, EF and mass. Table 2 shows the M-mode echocardiographic variables. After six months of therapy, LVESD and LVEDD were both reduced, without a significant increase in fractional shortening. Left atrial diameter and septal thickness remained unaffected. Two-dimensional echocardiography revealed a significant decrease of the transverse (6.8 Ϯ There was a significant decrease in both LVEDV and LVESV after six months of CRT, whereas EF showed a modest increase. Intra-observer variability was 8.4 Ϯ 6.4% for LVEDV and 9.4 Ϯ 7.1% for LVESV, compared with 33 Ϯ 30% for EF. For inter-observer variability, the corresponding values were 7.4 Ϯ 5.7%, 9.3 Ϯ 5.6% and 34.6 Ϯ 37.2%, respectively. There was no change in LV mass (372 Ϯ 120 vs. 387 Ϯ 144 g, p ϭ NS) or mean heart rate (78.5 Ϯ 17.2 vs. 74.4 Ϯ 20.2 beats/min, p ϭ NS).
Comparison of responders and stable patients versus nonresponders.
Sixteen patients showed a reduction of Ͼ15% in LVESV; five were stable; and only four were classified as nonresponders. These four patients had a significantly higher mean baseline LVEDV value ( Table 3) . The baseline volumes of responders (LVEDV: 232 Ϯ 78 ml; LVESV: 187 Ϯ 74 ml) and stable patients (LVEDV: 243 Ϯ 62 ml; LVESV: 180 Ϯ 52 ml) did not differ significantly. There were no significant differences in baseline EF between the groups. After six months of CRT, EF showed an increase only in volume responders (22 Ϯ 7% to 28 Ϯ 8%, p Ͻ 0.001), whereas the nonresponders showed a nonsignificant decrease in EF (20 Ϯ 10% to 17 Ϯ 6%, p ϭ NS). Eleven of 16 volume responders were receiving beta- No correlation between baseline volumes and the early increase in either aortic pulse pressure or ϩdP/dt induced by CRT was observed ( Fig. 4A and 4B ). Volume nonresponders were found among those with very large and only minimal early hemodynamic response.
DISCUSSION
Main findings. This study demonstrates that CRT achieved by hemodynamically optimized pacing leads to a long-term reduction in LV volumes in the majority of patients with systolic HF and ventricular conduction disturbances. Recent data in larger populations have indicated reduced LVEDD after CRT (15) . However, measurements of LV volumes are more reliable in assessing LV remodeling (16) . The fact that the effect on LV diameters was more pronounced for the transverse than for the longitudinal diameter underscores a "reverse remodeling" effect caused by CRT, although changes in the derived sphericity index failed to reach statistical significance because of a minor, nonsignificant decrease in the longitudinal LV diameter. The spherical shape in dilated hearts is associated with increased wall stress (17) , and changes in LV sphericity have been correlated to an increase in exercise capacity (18) .
Effect on MR.
Some investigators have speculated that LV-based pacing leads to a reduction in MR (19) , which can be explained by 1) a reduction in presystolic MR by optimizing atrioventricular delay and 2) a reduction in systolic MR by improved coaptation of the valve leaflets, which may be impaired by delayed contraction of the anterolateral papillary muscle. The sphericity associated with LV dilation leads to functional MR (20) ; thus, reversal of this process may reduce MR. However, the degree of baseline MR in our study was low; thus, despite the fact that some reduction was noted, it seems unlikely that this was the prevailing mechanism for LV volume reduction. Prediction of volume response. Some patients did not respond to CRT with a reduction in LV volumes, and the extent of the early hemodynamic response was not a good predictor of volume effects. In fact, three of four volume nonresponders were among those with the largest early hemodynamic improvement. Thus, other factors are involved in the reverse remodeling response to CRT, such as baseline geometry and LV size. The fact that volume nonresponders had a higher mean LVEDV is in concordance with data from drug trials indicating that nonresponders to pharmacologic therapy had higher baseline LVEDD values (21) . However, our data do not yet allow for the conclusion that CRT is not indicated in very dilated hearts, because the positive early hemodynamic effects of CRT can still lead to symptomatic improvement despite the lack of volume reduction, as shown by a similar improvement in NYHA functional class in volume nonresponders. Moreover, we could not define a cut-off value above which a reduction in LV volumes can no longer be expected. Interaction with drug treatment. A dose-related "reverse remodeling effect" in HF has been described for betablocker treatment (22, 23 ). An additive effect of betablockers on volumes in our study cannot be completely ruled out, because there were more volume responders than nonresponders receiving beta-blocker therapy. However, patients were receiving stable drug therapy before study inclusion, and dose adjustments during the study were minor, as indicated by the lack of a significant change in heart rate. Moreover, recent data suggest that patients with a QRS width Ͼ120 ms, as in our study, are less likely to respond to beta-blocker therapy with an improvement in EF, compared with patients with a narrow QRS width (24) . It is also noteworthy that 5 of 16 volume responders were not taking beta-blockers. We believe that CRT is complementary to beta-blockers because: 1) it leads to an improvement in exercise capacity (4), which has not been consistently shown for beta-blockers; 2) it minimizes the risk of bradyarrhythmias; and 3) it can be useful in the early treatment phase to overcome the initial negative inotropy and hypotension associated with beta-blockers. Cardiac resynchronization therapy is an attractive alternative to positive inotropic drug therapy for this purpose, because the hemodynamic benefit achieved by CRT is associated with a reduction in myocardial oxygen demand (25) . The reason for this is a more efficient systolic contraction, which leads to a reduction in regional wall stress, because areas of delayed activation, such as the LV free wall in LBBB, are known to have greater regional wall stress (26) . A reduction in both wall stress and oxygen demand with CRT can lead to a decrease in sympathetic nervous activation (27) , which may contribute to a reduction in LV size. Study limitations. The number of patients analyzed was small, and the changes observed need to be verified in larger patient cohorts. Because no control group was studied, a positive effect of the close medical follow-up, rather than CRT, cannot be ruled out. The cross-over period during the first three months after implantation may have affected the results because different pacing modes were used and patients were not paced during the second month. However, the differences in the early hemodynamic response between optimal univentricular (LV in most cases) and BV pacing were minor (2), and patients were constantly paced for the last four months before echocardiographic re-evaluation. Thus, we believe that the data are not invalidated by the cross-over period. The study was not designed to assess the impact of CRT on the severity of MR. Thus, no systematic, prospective evaluation of MR severity was performed. The modified Simpson's rule was used for LV volume calculation, which may not be optimal for the spherical shape and asymmetrical contraction in the hearts examined. With the disco-ordinated contraction in LBBB, the smallest cavity area may not truly represent the end of systole, as late activated areas may still be contracting. Finally, echocardiographic data have not been correlated to functional variables.
Conclusions. The data of this study indicate that longterm CRT leads to a reduction in LV volumes in the majority of patients with advanced HF and ventricular conduction disturbances. Patients with higher baseline volumes are less likely to show a decrease in volume. The mechanisms leading to this "reverse remodeling" effect are incompletely understood, but may involve a reduction in regional wall stress, myocardial oxygen demand and functional MR. Further studies in larger patient cohorts are needed to more clearly define the clinical characteristics of patients who show reverse remodeling by CRT.
